| ［1］ CocaPelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck—an update［J］. Oral Oncol, 2015, 51(7): 652-661. DOI: 10.1016/j.oraloncology.2015.04.005. ［2］ Damborenea Tajada J, Campos del Alamo MA, Marín García J, et al. Adenoid cystic carcinoma of the larynx. Case report and literature review［J］. An Otorrinolaringol Ibero Am, 1999, 26(3): 257-263. ［3］ Amit M, Binenbaum Y, Sharma K, et al. Incidence of cervical lymph node metastasis and its association with outcomes in patients with adenoid cystic carcinoma. An international collaborative study［J］. Head Neck, 2015, 37(7): 1032-1037. DOI: 10.1002/hed.23711. ［4］ 刘文胜, 唐平章, 祁永发, 等. 腭部腺样囊性癌的诊治及预后因素的探讨［J］. 中华肿瘤杂志, 2004, 26(8): 485-489. DOI: 10.3760/j.issn.0253-3766.2004.08.012. ［5］ Wu D, Liang L, Nie L, et al. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: apatinib treatment in nonsquamous NSCLC［J］. Asia Pac J Clin Oncol, 2018, In press. DOI: 10.1111/ajco.12870. ［6］ Hu X, Zhang J, Xu B, et al. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triplenegative breast cancer［J］. Int J Cancer, 2014, 135(8): 1961-1969. DOI: 10.1002/ijc.28829. ［7］ Kong Y, Sun L, Hou Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma［J］. Oncotarget, 2017, 8(62): 105596-105605. DOI: 10.18632/oncotarget.22337. |
